Imipenem-Cilastatin Dosing After Hemodialysis with Schedule Changes
For patients on hemodialysis requiring imipenem-cilastatin for sepsis control, administer 500 mg after each dialysis session, regardless of whether the dialysis schedule changes from three times weekly to daily or vice versa—the key principle is always dosing immediately post-dialysis with intervals timed from the end of each session.
Core Dosing Principle for Hemodialysis Patients
The FDA label provides explicit guidance: both imipenem and cilastatin are cleared during hemodialysis, and the patient should receive imipenem-cilastatin after hemodialysis with intervals timed from the end of that hemodialysis session 1. This post-dialysis timing is critical because:
- Approximately 40% of the dose is removed if given just before hemodialysis 2
- Administering after dialysis prevents premature drug removal and facilitates directly observed therapy 2
- This approach avoids underdosing while preventing accumulation between sessions 2
Specific Dosing Recommendations
For patients with creatinine clearance <15 mL/min on hemodialysis:
- Standard dose: 500 mg imipenem/500 mg cilastatin after each dialysis session 1
- Alternative for less susceptible organisms: 500 mg every 12 hours (using the dosing for CrCl <30 to ≥15 mL/min) 1
- The dose itself does not change with dialysis frequency—only the timing relative to dialysis sessions matters
When Dialysis Schedule Changes
Three Times Weekly → Daily Dialysis
- Continue 500 mg post-dialysis
- Now administered daily instead of three times weekly
- No dose adjustment needed—the post-dialysis principle remains constant 1
Daily Dialysis → Three Times Weekly
- Continue 500 mg post-dialysis
- Now administered three times weekly instead of daily
- Monitor closely as the longer interdialytic interval may allow some drug accumulation, particularly of cilastatin 3, 4
Critical Pharmacokinetic Considerations
Imipenem versus cilastatin clearance differs substantially:
- Imipenem: Terminal half-life ~4 hours in anephric patients; maintains some non-renal metabolic clearance 5, 4
- Cilastatin: Terminal half-life ~16 hours in anephric patients; minimal non-renal clearance, leading to accumulation 5, 4
- During hemodialysis, cilastatin clearance increases 335-600% while imipenem clearance increases only 15-25% 6
This differential clearance justifies the fixed 500/500 mg combination twice daily in renal failure patients on dialysis, as dialysis reverses cilastatin accumulation 6, 7.
Monitoring and Safety
Essential monitoring parameters:
- Therapeutic drug monitoring should be considered to ensure adequate absorption without excessive accumulation 2
- Seizure risk increases in patients with CrCl <30 mL/min, especially those with background CNS disease 1
- Dialysis patients should be carefully monitored; use only when benefit outweighs seizure risk 1
- Maintain therapeutic imipenem trough levels ≥4 mg/L for 8-10 hours post-dose 7
Common Pitfalls to Avoid
- Never dose before dialysis—this wastes 40% of the dose through dialysis removal 2
- Don't reduce the dose—imipenem exhibits concentration-dependent bactericidal activity; smaller doses reduce efficacy 2
- Don't assume peritoneal dialysis follows the same rules—insufficient data exist for peritoneal dialysis dosing 2, 1
- Don't forget the loading dose principle—even in renal failure, the initial dose should be a full 500 mg to achieve rapid therapeutic levels given expanded volume of distribution in septic patients 8
Sepsis-Specific Considerations
In septic patients on dialysis:
- Always use a full loading dose (500 mg) initially, as volume of distribution is expanded due to fluid resuscitation 8
- Loading dose is independent of renal function 8
- For severe sepsis/septic shock, consider that suboptimal antibiotic levels markedly increase mortality 8
- The post-dialysis dosing schedule maintains adequate drug exposure while preventing toxicity 7, 3